Akebia reports Q2 EPS (4c), consensus (5c)

Reports Q2 revenue $43.65M, consensus $49.45M. “Since receiving FDA approval in late March, our key priority has been to execute on our launch strategy developed with a goal for Vafseo to become the standard of care in the treatment of anemia for dialysis patients,” said John Butler, Chief Executive Officer of Akebia. “Our team is actively engaged with prescribers, and I’m extremely encouraged by the positive reception we’ve seen across the kidney community for a new choice in anemia management. Equally important, our commercial team is now in active discussions with dialysis organizations covering the vast majority of patients to contract both Auryxia and Vafseo, giving our team a unique opportunity to contract across the portfolio.”